abstract In this issue of Blood, Bhoj et al explore the longevity of plasma cells (PCs) and humoral immunity in the absence of B cells. This is done by studying subjects experiencing B-cell aplasia after CD19-directed chimeric antigen receptor (CAR) therapy.
